<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-TNC-09000399</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2009-04-22</date_registration>
      <primary_sponsor>Zhongshan Hospital, Fudan University</primary_sponsor>
      <public_title>Research on Induction of Renal Transplant tolerance</public_title>
      <acronym />
      <scientific_title>Donor Hematopoietic Stem Cells to Induce Tolerance in Kidney Transpant Recipients</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2009-03-01</date_enrolment>
      <type_enrolment />
      <target_size>Study group:10;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=9134</url>
      <study_type>Observational study</study_type>
      <study_design>Before-After control</study_design>
      <phase>I (Phase I study)</phase>
      <hc_freetext>End stage renal failure, renal transplantation</hc_freetext>
      <i_freetext>Study group:irradiation, ATG, Renal and Hematopoietic-Cell Transplantation  ;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Xuanchuan Wang</firstname>
        <middlename />
        <lastname />
        <address>No.180, Fenglin Road, Xuhui District, Shanghai, China</address>
        <city />
        <country1 />
        <zip>200032</zip>
        <telephone>+86 0 13774267928</telephone>
        <email>0256039@fudan.edu.cn</email>
        <affiliation>Zhongshan Hospital, Fudan University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Tongyu Zhu</firstname>
        <middlename />
        <lastname />
        <address>No.180, Fenglin Road, Xuhui District, Shanghai, China</address>
        <city />
        <country1 />
        <zip>200032</zip>
        <telephone>+86 0 13311920325</telephone>
        <email>tyzhu@fudan.edu.cn</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Patient fully informed, signed informed consent;
2. Patient is receiving first renal transplant: living related;
3. HLA match 3 to 6 locus, PRA&lt;=10%, Negative lymphocyte cytotoxicity; 
4. Patient has good compliance and agrees to follow-up regularly;
5. Weight &gt;=40 kg.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Patient previously received/receiving transplant other than kidney;
2. Weight &lt;40 kg or BMI &gt; 30;
3. Recipient/donor is ELISA positive for human immunodeficiency virus (HIV), antibody positive for hep. C, or surface antigen positive for hep. B;
4. Recipient/donor is positive for TB;
5. Patient has current uncontrolled infections;
6. Patient has current malignancy or history of malignancy within past 5 years;
7. Patients has significant liver disease;
8. Patients has significant cardiac or lung disease;
9. CMV/EBV negative recipients of CMV/EBV positive donor; 
10. Patient does not have good compliance and agree to follow-up regularly.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Liver function;Chimerism;Renal function;Lymphocyte cytotoxicity;Biopsy;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Urine routine;CsA C0,C2;MMF AUC;Blood routine and lymphocyte type;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zhongshan Hospital, Fudan University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2009-04-02</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>